Market Intelligence, Preclinical Progress, and High-Purity Reagents for Neuroscience & Oncology Target Validation.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GPRIN1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GPRIN1 Full-Length Recombinant Protein (High purity >95%, Sequence Verified, E. coli/HEK293) | View GPRIN1 Products |
| Gene Delivery | GPRIN1 Promise-ORF / Lentivirus (Full-length ORF for stable cell lines, titer >1x10^8 TU/ml) | View GPRIN1 Products |
| Research Antibody | Anti-GPRIN1 Recombinant Antibody (Sequence-verified, high specificity for WB/IP) | View GPRIN1 Products |
| Validator | GPRIN1 siRNA Set (3 unique sequences for knockdown verification) | View GPRIN1 Products |
| Related Target: GNAO1 | GNAO1 (Gαo) Recombinant Protein – Direct binding partner for PPI assays | View GNAO1 Products |
| Related Target: GNAI1 | GNAI1 Recombinant Protein – Alternative Gαi/o subunit for cross-reactivity assessment | View GNAI1 Products |
| Related Target: GPRIN2 | GPRIN2 Recombinant Protein – Subfamily homolog for selectivity counter-screening | View GPRIN2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| GPRIN1-Gαo/Gαi PPI Quantification | Matched pair: Full-length GPRIN1 + GNAO1/GNAI1 proteins, >95% purity, suitable for SPR/BLI |
| Cross-species Preclinical Translation | Ortholog panel (Human/Mouse/Cyno) with >95% sequence homology verified |
| Subfamily Selectivity (GPRIN1 vs GPRIN2/3) | Homolog panel proteins strictly verified by mass spec |
| Neuronal Cell Line Construction | Lentivirus particles with full-length ORF; titer >1x10^8 TU/ml, puromycin selection |
| False Positives / Off-target siRNA Effects | Validated siRNA set for knockout phenotype rescue; endotoxin <1 EU/μg |
Live GPRIN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
GPRIN1 (G Protein Regulated Inducer of Neurite Outgrowth 1) is an emerging intracellular scaffold protein that serves as a cytosolic effector of Gαi/o signaling. It plays a dual role in promoting neurite outgrowth in neurons and regulating cell migration in cancer. Current preclinical research is exploring GPRIN1 modulation for neurodegenerative diseases (Alzheimer's, Parkinson's), neuropsychiatric disorders, and solid tumors (neuroblastoma, gastric cancer, lung cancer). Key therapeutic modalities include small molecule PPI inhibitors, PROTAC degraders, peptide disruptors, and RNAi/ASO therapies. The field is shifting from basic target validation to active drug discovery, with increasing demand for high-quality recombinant proteins, validated antibodies, and lentiviral tools.
Key Mutations in GPRIN1
The following mutations have been documented in the UniProt database for GPRIN1:
| dbSNP ID | Mutation Description | Evidence |
|---|---|---|
| rs17854765 | UniProt Q7Z2K8 VAR_063136 | UniProt |
| rs6556276 | UniProt Q7Z2K8 VAR_063137 | UniProt |
| rs10037225 | UniProt Q7Z2K8 VAR_056902 | UniProt |
These variants may affect protein structure or function and are important for designing selective assays and understanding inter-individual variability.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitor | Academic labs, Early-stage biotech | Neuroblastoma, Alzheimer's, Solid tumors (gastric/lung) | SPR/BLI with purified GPRIN1-GNAO1/GNAI1 pair |
| Peptide Disruptor | Biotech startups | Parkinson's disease | Competitive binding (Fluorescence Polarization) |
| PROTAC Degrader | Emerging platforms | Refractory cancers (neuroblastoma, solid tumors) | Ternary complex formation, degradation kinetics (require benchmark antibodies) |
| Genetic Modulation (siRNA/ASO) | Academic consortia, Preclinical | Opioid addiction, chronic pain, neuro-oncology | Knockdown validation with validated siRNA and lentiviral models |